David R. Bauer
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/25898_drbauer.jpg?itok=Y1b0J_im)
Filters
iRhythm Technologies, Inc. $115 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies, Inc…
Insulet Corporation Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…
Forty Seven, Inc. $86 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $86.25 million public offering of common stock of Forty Seven, …
Medtronic Global Holdings S.C.A. €5 Billion Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €5 billion aggregate principal amount of notes by Medtronic Global…
Gamida Cell Ltd. $35 Million Follow-On Offering
Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq…
The Medicines Company $172.5 Million Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227,273 shares of common stock for approximately $172.5 million, which…
Personalis, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed…
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
Orchard Therapeutics plc Approximately $128 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…